- Precision BioSciences is Simultaneously Advancing Development of PBCAR0191, as Potential First-in-Class, and PBCAR19B as Potential Best-in-Class CD19 Targeting Allogeneic CAR T Therapies - High Response Rates to PBCAR0191 Observed in Heavily Treated Patients Who Relapsed Following Prior